Clinical-stage Opportunity Aelis Farma is a clinical-stage biopharma focusing on brain disorders with two drug candidates in trials (AEF0117 and AEF0217), presenting multiple near-term collaboration or licensing opportunities for CNS diseases and cannabis-use related therapeutics.

CB1-SSi Advantage The company’s signaling specific inhibitors of the CB1 receptor offer a differentiated mechanism that may address unmet needs across various brain pathologies, creating potential for co-development or strategic partnerships in neurology, psychiatry, and neurodevelopmental areas.

Down Syndrome Focus AEF0217 targets cognitive deficits including Down syndrome with ongoing early-phase trials, signaling a potential entry point for partnerships with academic centers, patient organizations, or pharma seeking indications in neurodevelopmental disorders.

Cannabis-use Disorder AEF0117’s progression for cannabis use disorder, including existing Phase 2b activity, opens dialogue for collaborations with addiction treatment providers, behavioral health platforms, and payer networks interested in novel therapies for substance use disorders.

Regional & Investor Interest Strong regional funding and collaboration history from Nouvelle-Aquitaine, Inserm Transfert Initiative, Bpifrance, and other regional funds indicates a receptive environment for co-financing, sponsored research, and regional market access considerations in Europe.